Investor Presentation

July 30, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Investor Presentation Pursuanttoregulation30oftheSEBI(ListingObligationsandDisclosureRequirements)Regulations, 2015, we are enclosing herewith the Investor Presentation – Q1 FY 26-27. You are requested to take the same on record. Thanking You. Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office: Registered Office: Technopolis Knowledge Park, A wing, Office No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumbai – 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Investor Presentation Q1 FY27 Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Alivus Life Sciences Ltd. Financial Performance Review Q1 FY27 | Highlights “We are pleased to begin the first quarter of FY27 on a positive note demonstrating the resilience of our business model, strong execution and accelerating traction in the non-GPL business. With recently launched products continuing to gain scale across geographies, we remain confident in the Dr. Yasir Rawjee sustainability of this momentum. Managing Director & GPL business is expected to be flattish in FY27, despite a significant decline in Q1FY27. GPL Chief Executive Officer business has historically been skewed towards H2 and the same is expected in FY27 as well. With a continued strong growth momentum in the non-GPL portfolio and muted growth in the GPL business, we remain confident of achieving revenue growth of 10% - 12% in FY27, while sustaining EBITDA margins in the 30%–32% range. At the same time, our ongoing investments in capacity expansion and pipeline development are strengthening the foundation for future growth." • Growth was anchored by non-GPL business which grew 27.6% QoQ & 26.5% YoY. This was REVENUE 6,404 -7.1% 6.4% driven by strong momentum across all geographies, reflecting healthy demand and effective QoQ YoY (IN ₹ MILLION) execution. • Gross Margins were at 60.2%, up 510 bps YoY, on the back of favorable product mix and new EBITDA 2,341 -1.3% 29.1% launches. QoQ YoY (IN ₹ MILLION) • EBITDA Margins for the quarter were at 36.6%, up 220 bps QoQ & 650 bps YoY, signifying better operational efficiencies. PAT 1,601 -1.6% 31.8% • PAT Margins for the quarter were at 25.0% up 140 bps QoQ & 480 bps YoY. QoQ YoY (IN ₹ MILLION) • The company generated a strong free cash flow of ₹ 901 Mn, leading to Cash and Cash Equivalents (including short term investments) of ₹ 8,802 Mn as of 30th June 2026. GPL: Glenmark Pharmaceuticals Ltd. Q1 FY27 Performance Revenue EBITDA PAT EPS (In ₹ Million) (In ₹ Million) (In ₹ Million) (In ₹) PAT Margin EBITDA Margin 6 98, 36.4% 36.6% 23.6% 25.0% 31 1 927, 1 33.0% 34.4% 22.1% 22.3% 21 32. 40.3 404,6 30.1% 254,2 373,2 143,2 20.2% 305,1 726,1 106,1 19.9 06.01 88,5 9,1 2,1 103, 0 8, 93 51 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 P&L Highlights | Q1 FY27 Particulars (In ₹ Million) Q1 FY27 Q4 FY26 QoQ Q1 FY26 YoY FY26 Revenue from Operations 6,404 6,891 -7.1% 6,018 6.4% 25,518 Gross Profit 3,854 4,182 -7.8% 3,315 16.3% 14,853 Gross Profit (%) 60.2% 60.7% -50 bps 55.1% +510 bps 58.2% Other Income 224 228 -1.8% 90 148.9% 604 Employee Benefits Expense 683 781 -12.5% 616 10.9% 2,725 Other Expenses 1,054 1,256 -16.1% 976 8.0% 4,155 EBITDA 2,341 2,373 -1.3% 1,813 29.1% 8,577 EBITDA Margin (%) 36.6% 34.4% +220 bps 30.1% +650 bps 33.6% Depreciation and Amortisation 206 202 2.0% 171 20.5% 753 Finance Costs 13 13 0.0% 12 8.3% 53 PBT (before exceptional items) 2,122 2,158 -1.7% 1,630 30.2% 7,771 Exceptional items - - - - - 257 PBT (after exceptional items) 2,122 2,158 -1.7% 1,630 30.2% 7,514 PBT Margin (%) 33.1% 31.3% +180 bps 27.1% +600 bps 29.4% PAT 1,601 1,627 -1.6% 1,215 31.8% 5,645 Net Margin (%) 25.0% 23.6% +140 bps 20.2% +480 bps 22.1% Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) 32% 32% 27% 2.7 2.2 2.2 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 • ROICE is tracking at ~32% – Capital employed was driven by a calibrated Capex strategy • FATR is 2.2 times – Asset turns have trended slightly lower due to the Capex cycle • Strong Balance Sheet – Strong free cash generation of ₹ 901 Mn leading to Cash and Cash Equivalents (including short term investments) of ₹ 8,802 Mn as of June 30, 2026 Robust Growth & Steady Profitability Revenue EBITDA PAT EPS (In ₹ Million) (In ₹ Million) (In ₹ Million) (In ₹) EBITDA Margin PAT Margin 33.6% 52 31.4% 31.1% 30.1% 30.0% 21.6% 22.1% 4 2 5, 20.6% 20.3% 5 8,3 81 19.7% 232,12 216,12 238, 96 217,6 368,6 271,7 775, 076,4 907,4 758,4 546, 36.53 11.83 34.83 36.93 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Business Performance Review Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenue In ₹ Million) (Revenue In ₹ Million) 6,343 6,070 5,921 5,513 5,464 378 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1Y27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1Y27 • CDMO business saw a growth of 3.8% YoY in Q1FY27. CDMO contribution from new and • Generic API revenues in Q1FY27 saw a growth existing projects continues and is expected to of 7.4% YoY, despite a significant decline in the 94% 6% translate into better growth in H2FY27. GPL business. • Several projects are in advanced stage of discussions. Segmental Performance | GPL vs Non-GPL GPL Non-GPL % of Total Revenue % of Total Revenue (In ₹ Million) (In ₹ Million) 35.4% 88.7% 30.0% 75.6% 74.6% 25 [Showing first 8,000 characters — download PDF for full document]